Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Drug Farm

News headline image
Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline
From Drug Farm
Via Business Wire
News headline image
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
From Drug Farm
Via Business Wire
News headline image
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces U.S. FDA Orphan Drug Designation for DF-003 for the Treatment of ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces FDA Acceptance of DF-003 into Rare Disease Evidence Principles Process for ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces Agreement with Cincinnati Children’s Hospital Medical Center to Explore ALPK1 Inhibitor, DF-003 as a Potential Treatment for Heart Disease and Blood Cancers Driven by Clonal Hematopoiesis
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces Publication in Nature Communications Describing the Discovery and Preclinical Characterization of First-in-Class ALPK1 inhibitor, DF-003
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces First Patients Dosed in Phase 1b Clinical Trial Evaluating ALPK1 Inhibitor, DF-003 in ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Reports Data on Safety and Pharmacokinetics from Phase 1 First-in-Human Trial of DF-003 in Healthy Volunteers
From Drug Farm
Via Business Wire
News headline image
Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer
From Drug Farm
Via Business Wire
News headline image
Drug Farm Signs Agreement with National Institutes of Health (NIH) to Develop Precision Targeted Treatment for ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces anti-HBV immunomodulator, DF-006 is Accepted as a Late-Breaking Presentation at the 2024 European Association for the Study of the Liver Conference
From Drug Farm
Via Business Wire
News headline image
Drug Farm Receives Rare Pediatric Disease Designation from the U.S. FDA for DF-003 to Treat ROSAH Syndrome
From Drug Farm
Via Business Wire
News headline image
Drug Farm Doses First Patient in Part 3 of Phase 1 Chronic Hepatitis B Trial
From Drug Farm
Via Business Wire
News headline image
Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003
From Drug Farm
Via Business Wire
News headline image
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral ALPK1 Selective Kinase Inhibitor, DF-003
From Drug Farm
Via Business Wire
News headline image
Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials
From Drug Farm
Via Business Wire
News headline image
Drug Farm Appoints Dr. Jeysen Yogaratnam as Chief Medical Officer
From Drug Farm
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.